Wigle, Tim J

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology

Epigenetics and DNA MethylationCancer-related gene regulation

Cited by 776

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology

Cancer-related gene regulationProtein Degradation and Inhibitors

Cited by 569

Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor

Mitchell, L. H., Boriack-Sjodin, P. A., Smith, S., Thomenius, M., Rioux, N., Munchhof, M., Mills, J. E., Klaus, C., Totman, J., Riera, T. V., et al. (2016) · ACS Medicinal Chemistry Letters

Cancer-related gene regulationEpigenetics and DNA Methylation

Cited by 91

Abstract 5789: Discovery of a selective molecular glue degrader of CCNE1 for the treatment of CCNE1-amplified solid tumors and CDK4/6i-resistant HR+/HER2- breast cancers

Vincent, B. M., Marcoux, D., Caligioni, C., Bart, A. G., Harlow, M. L., Hsu, R. Y., Singh, P., Badger, R., Ingersoll, A. J., Jordan, T. B., et al. (2026) · Cancer Research

Protein Degradation and InhibitorsAdvanced Breast Cancer Therapies

Cited by 1